Journey Medical Corporation DERM R2KPHARMA
Company Overview
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Recent Developments
- Dec 2025 Revenue of $61.24M (+11.1% YoY); net profit $-11.43M.
- Trailing 12 Months Year-on-year growth — revenue +23.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.58% |
| 1 Year: | 23.30% |
Stock Price Performance
| 1 Year: | -30.76% |
| 6 Months: | -2.52% |
| 3 Months: | -21.19% |
| 1 Month: | -20.57% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross1d ago
- RSI (14)34.50 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 45.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DERM Journey Medical Corporation R2KPHARMA | 5.02 | -22.82 | $111.57M | 0.00% | -14.30% | -23.77% | 6.58% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.45M | 10.72M | 15.29M | 19.61M | 20.80M | 18.23M | 16.04M | 12.16M | 16.96M | 15.28M | 13.03M | 14.86M | 14.63M | 13.14M | 15.01M | 17.02M | 15.92M |
| Operating Income | 239.00K | 585.00K | -13.76M | -12.65M | -888.00K | -7.14M | -9.49M | -9.56M | -7.65M | 17.25M | -10.09M | -2.93M | -2.89M | -3.32M | -2.88M | -1.53M | -1.49M |
| Net Income | 29.00K | 268.00K | -11.87M | -10.65M | -1.38M | -7.53M | -10.08M | -10.14M | -8.36M | 16.79M | -10.44M | -3.36M | -2.39M | -4.07M | -3.80M | -2.31M | -2.23M |
| Diluted EPS | 0.00 | 0.02 | -1.30 | -1.16 | -0.08 | -0.43 | -0.57 | -0.57 | -0.46 | 0.80 | -0.53 | -0.17 | -0.12 | -0.18 | -0.16 | -0.09 | -0.08 |
| R&D Expense | - | - | 29.00K | 718.00K | 1.27M | 2.61M | 2.81M | 2.03M | 1.77M | 2.23M | 7.88M | 913.00K | 842.00K | 39.00K | - | 287.00K | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 44.53M | 63.13M | 71.00M | 59.66M | 55.13M | 61.24M |
| Operating Income | 7.85M | -34.88M | -27.52M | -2.07M | -13.68M | -8.17M |
| Net Income | 5.28M | -43.99M | -29.63M | -3.85M | -14.67M | -11.43M |
| Diluted EPS | 0.49 | -4.32 | -1.69 | -0.21 | -0.72 | -0.47 |
| R&D Expense | - | 2.74M | 10.94M | 7.54M | 9.86M | 480.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 51.91M | 97.28M | 105.16M | 76.85M | 80.24M | 94.59M |
| Total Equity | 2.75M | 10.29M | 42.04M | 16.98M | 20.35M | 20.07M | 31.85M |
| Cash & Equivalents | - | 8.25M | 49.08M | 32.00M | 27.44M | 20.30M | 24.09M |
| Long Term Debt | - | - | - | 19.83M | 14.62M | 24.88M | 25.28M |
| Total Liabilities | - | 41.61M | 55.24M | 88.18M | 56.50M | 60.17M | 62.74M |
| Current Liabilities | - | 28.06M | 51.61M | 66.83M | 41.87M | 35.17M | 37.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 5.13M | - | -13.53M | 5.24M | -9.13M | -12.44M |
| Investing Cash Flow | -1.20M | - | -20.00M | -5.00M | -15.00M | 0 |
| Financing Cash Flow | -487.00K | - | 16.46M | -4.80M | 16.99M | 16.23M |
| Capital Expenditure | - | -10.00M | -20.00M | -5.00M | -15.00M | - |
| Free Cash Flow | - | - | -33.53M | 240.00K | -24.13M | -12.44M |
| Net Change in Cash | - | - | -17.08M | -4.56M | -7.13M | 3.79M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | 17.6% | -55.2% | -38.8% | -3.5% | -24.8% | -13.3% |
| Net Margin % | 11.9% | -69.7% | -41.7% | -6.5% | -26.6% | -18.7% |
| ROE % | 51.3% | -104.6% | -174.5% | -18.9% | -73.1% | -35.9% |
| ROCE % | 32.9% | -76.4% | -71.8% | -5.9% | -30.3% | -14.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Wasatch Advisors LP | 12.86% | 2.86M | $18.04M |
| 2 | Tang Capital Management, LLC | 7.24% | 1.61M | $10.16M |
| 3 | Vanguard Capital Management LLC | 3.04% | 675.18K | $4.26M |
| 4 | Punch & Associates Investment Management, Inc. | 2.41% | 536.00K | $3.38M |
| 5 | Pale Fire Capital SE | 2.38% | 528.58K | $3.34M |
| 6 | Opaleye Management Inc. | 1.57% | 350.00K | $2.21M |
| 7 | Summit Financial, LLC | 1.56% | 346.75K | $2.19M |
| 8 | Jane Street Group, LLC | 1.44% | 320.02K | $2.02M |
| 9 | Diametric Capital, Lp | 1.33% | 295.66K | $1.87M |
| 10 | Ikarian Capital, LLC | 1.13% | 251.44K | $1.59M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DERM
Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOS0drb2N0b0xKQ3F1U3BVelBTN1h3SENMSUR5Ry1pbVZKdGxEY0JiMlEzeHB5WnIyMGstbEptLXNFWUpwT0xld0lyMHdMamxCVWNDblp1ZzR2SnA4NVA1MlhnV1lSMlR3a2N0MFZCdFBoeUVpYnNLeHNNY0VzYUduUW9tMGxBeS1WaFVyU0…
ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy? - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNdHkxemM5YzBmbk1PMGoxYkJUQ3RlUVNFVVpqNlQ5RFdKLUlzdzREdkI5MW93RkhfMHU3bVFEd2xSQ05kV0xiVE9jdVN6NWhhN01uWEwtWHZsM29hRnlMeUhpeFV6NXI3X1Zmd01Odk0yamhJdHVwZDhEemZWOTNyU0xJcWZnSkJwTXI2Mk…
DERM Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1kMnZIZEtEM293dGU0OHpaZUE1ZklBcmNReDRqTm52SHVGVHdmTG43eTJsVk9EVlFFaUU3Z24wM3pDUmlwbjBpeGpOMjVPc1R0Vkt4c2ROMGxFZi1MSFAwaDlDN1lMWHBPSTFXVTMxV1c5cUZyYWtDV25B?oc=5" target="_blank">DER…
Journey Medical (NASDAQ:DERM) Stock Moved Down to "Hold" by Wall Street Zen - MarketBeat
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOSmJ6Z1U3QlpUSnhwX3lReHNhbk5XNFYxUFlSVE0zaVJIR1o3WEpza1NQdVVRUk4xbTl2OXNOZGFDd3NEZGFkdUVjRWJmdVhFZTliUUlyYWRObnRJTzZqZENhbTlKM1gyeWZzeG9iZzl0WnJkeG9sbXhtcGRVN29vZEJkekhVeFd1SS1Man…
Journey Medical: A Small Pharma With A Large Growth Opportunity (NASDAQ:DERM) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNampPOWQ5dnVfVFpFcmJYZ2dnU24wNHRFU1VOOHd0VENYY24tNzZaU1hvY05fYnlUU29wbFM1dmJtMTl2R0s3cFM5NTZnLXU5TmdfQXNOWTlkR0hXNDhzTVppNTUydnN5Tk9mMW42SDVyUG16SUw4dEZMVk8zMFNLdWhqMFJkeFVkejhnbH…
An investment adviser reports passive ownership of 2.45M shares in Journey Medical (DERM). - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxONmNVZkpuOEViSmczUGVaWm5ORXNUcUdjMHJzaHl1RllmTHRCV2lSNzF2Vkh0SDFmcTdkVjQ0T1k0ZVI5Z1l3UFlJT2RKenY3OUs5emM2MTJiWmQ4cG8xT00yeE12aUFnbUFFVGJPVW5sa0Y5ZmZuMC10U2pjOU5XRnRmdzNUQ0oxcl8ycz…
DERM — Frequently Asked Questions
What is the current share price of Journey Medical Corporation (DERM)?
As of 2026-10-23 16:27 PDT, Journey Medical Corporation (DERM) trades at $5.02 on NasdaqCM. Its 52-week range is $4.39 to $9.26.
What is the market capitalisation of DERM?
Journey Medical Corporation (DERM) has a market capitalisation of $111.57M on NasdaqCM.
What is the P/E ratio of DERM?
DERM trades at a trailing price-to-earnings (P/E) ratio of -22.82. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 5.43.
What is the return on equity (ROE) of DERM?
DERM has a return on equity (ROE) of -23.77%. Its return on capital employed (ROCE) is -14.30%.
Is DERM a good stock to buy?
This page provides a data-driven analysis of Journey Medical Corporation (DERM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.